NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The overall objective is to improve the cure rate of children with newly diagnosed acute
myeloid leukemia (AML) who undergo risk-adapted therapy.
Stem cell transplantation (SCT) is reserved to high-risk patients defined by cytogenetics and
response to chemotherapy. The efficacy and toxicity of Gemtuzumab ozogamicin (GO, Mylotarg)
will be evaluated.